THE PLURICELLULARITY OF THE HEART, allowing an intense communication among cells and cell types in the myocardial tissue, has long been recognized (2). Adaptations within this communication network, mostly between endothelial cells, fibroblasts, and cardiomyocytes, are part of the autoregulatory properties of the heart during its role as the hemodynamic pump in the cardiovascular system, and participate during changes of ventricular contraction and relaxation, the development of ventricular hypertrophy, etc. Over the past 20 years, the neuregulin-1 (NRG1)/ErbB pathway has emerged as a prototypical example of cell communication in the heart (11, 17). NRG1, a member of the epidermal growth factor family, is synthesized by and released from endothelial cells in the myocardial microvasculature and in the endocardium. Its biological effects are mediated by tyrosine kinase receptors ErbB2, ErbB3, and ErbB4. NRG1 binds to ErbB4 (and ErbB3 in the fetal heart) on surrounding cardiac myocytes, leading to receptor (hetero-)dimerization, preferably with ErbB2, transphosphorylation of the dimer partners, and downstream signaling (17). The endothelial synthesis and release of NRG1 is controlled by hemodynamic and neurohormonal stimuli and is increased in (patho)physiological conditions such as pregnancy, heart failure, ischemia, etc. (7, 10, 13) .
reasoned that by identifying microRNAs regulated by NRG1 in embryonic stem cells (ESCs), they might discover new microRNAs important for cardiac differentiation of ESCs, hence contributing to the development of strategies for ESC-based cell therapies of cardiac repair. Stem cell therapy is a promising treatment option after ventricular injury, but gaps in the understanding of stem cell biology limit its clinical use (18) . An important challenge remains-the control of their differentiation into the cardiac lineage (20) .
The authors succeeded in their goal by microRNA profiling of ESCs during hanging drop-induced differentiation. ESCs were treated with either NRG-1 or a (nonspecific) ErbB inhibitor, thereby linking the differential expression of three microRNAs to NRG1-induced ErbB signaling in ESCs. Inhibition of each of these microRNAs influenced the cardiac differentiation of ESCs, showing their functional importance. Interestingly, in absence of NRG1, these microRNAs had a pattern of expression as if NRG1/ErbB signaling occurred as a spontaneous phenomenon during hanging drop-induced differentiation of ESCs, a finding that was confirmed in separate experiments. In conclusion, this study confirms the importance of NRG1/ErbB signaling during ESC differentiation into the cardiac lineage, and it identifies novel NRG1-controlled microRNAs as intermediate mediators of the cardiac lineage differentiation process.
Inherent to any successful experimental study, apart from revealing new scientific information, are the new scientific questions that it raises. First, one may wonder whether the identified set of microRNAs is part of a larger set of microRNAs, which may be characteristic of ESC differentiation into a cardiac cell lineage. Is a specific set of microRNAs coupled to NRG1-induced cardiac differentiation of ESCs, or are these microRNAs common to other mediators and conditions that promote a cardiac lineage? Does an inhibition of this set of microRNAs simply block ESC cardiac cell differentiation, or does such inhibition push differentiation toward a specific cardiac (beating vs. nonbeating) cardiac cell type? One of the weaknesses of this study is that it only assessed the effect of targeted microRNA inhibition on two molecular markers of differentiation, not on the regulation of the cardiac cell subtype. Accordingly, the study by Sun et al. paves the path of ESC-mediated cardiac regeneration by identifying intermediate microRNAs. The next step is to scrutinize how this new information contributes to the original goal of this study, i.e., the development of strategies for ESC-based cell therapies of cardiac repair. This study is another example of the central role that NRG1/ErbB signaling may play in future endeavors to reverse the pathophysiology of heart failure, either by stimulating ErbB signaling in vivo in the failing heart, or by cell therapy with NRG1-programmed ESCs (see Fig. 1 ). One may Fig. 1 . The physiological properties of the ventricular neuregulin-1/ErbB system in embryonic and adult life are beginning to be translated into novel clinical therapeutic approaches for the treatment of chronic heart failure. Further analyzing these physiological properties is important for estimating the opportunities and drawbacks of these approaches. NRG-1, neuregulin-1; ESC, embryonic stem cells.
